Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought
Jazyk angličtina Země Německo Médium print-electronic
Typ dokumentu časopisecké články
Grantová podpora
P30 CA008748
NCI NIH HHS - United States
PubMed
29721611
PubMed Central
PMC8177015
DOI
10.1007/s00345-018-2299-2
PII: 10.1007/s00345-018-2299-2
Knihovny.cz E-zdroje
- Klíčová slova
- Non-muscle invasive bladder cancer, Progression, Re-transurethral resection of the bladder, Recurrence,
- MeSH
- adjuvancia imunologická terapeutické užití MeSH
- aplikace intravezikální MeSH
- BCG vakcína terapeutické užití MeSH
- cystektomie metody MeSH
- lidé MeSH
- lokální recidiva nádoru mortalita MeSH
- nádory močového měchýře * mortalita patologie terapie MeSH
- následné studie MeSH
- příčina smrti MeSH
- progrese nemoci MeSH
- proporcionální rizikové modely MeSH
- reoperace MeSH
- retrospektivní studie MeSH
- senioři MeSH
- staging nádorů MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- adjuvancia imunologická MeSH
- BCG vakcína MeSH
PURPOSE: The goals of transurethral resection of a bladder tumor (TUR) are to completely resect the lesions and to make a correct diagnosis to adequately stage and treat the patient. Persistent disease after TUR is not uncommon and is why re-TUR is recommended in T1G3 patients. When there is T1 tumor in the re-TUR specimen, very high risks of progression (82%) have been reported. We analyze the risks of recurrence, progression to muscle-invasive disease and cancer-specific mortality (CSM) according to tumor stage at re-TUR in T1G3 patients treated with BCG. METHODS: In our retrospective cohort of 2451 T1G3 patients, 934 patients (38.1%) underwent re-TUR. 667 patients had residual disease (71.4%): Ta in 378 (40.5%), T1 in 289 (30.9%) patients. Times to recurrence, progression and CSM in the three groups were estimated using cumulative incidence functions and compared using the Cox regression model. RESULTS: During a median follow-up of 5.2 years, 512 patients recurred. The recurrence rate was significantly higher in patients with a T1 at re-TUR (P < 0.001). Progression rates differed according to the pathology at re-TUR, 25.3% in T1, 14.6% in Ta and 14.2% in case of no residual tumor (P < 0.001). Similar trends were seen in both patients with and without muscle in the original TUR specimen. CONCLUSIONS: Patients with T1G3 tumors and no residual disease or Ta at re-TUR have better recurrence, progression and CSM rates than previously reported, with a CSM rate of 13.1 and a 25.3% progression rate in re-TUR T1 disease.
Department of Biostatistics EORTC Headquarters Brussels Belgium
Department of Experimental and Clinical Medicine University of Florence Florence Italy
Department of Surgical Oncological and Stomatological Sciences University of Palermo Palermo Italy
Department of Surgical Science John Radcliffe Hospital University of Oxford Oxford UK
Department of Urology Academic Hospital Uppsala University Uppsala Sweden
Department of Urology Cochin Hospital Paris France
Department of Urology Fundacio Puigvert University of Barcelona Barcelona Spain
Department of Urology Mayo Clinic Rochester MN USA
Department of Urology Memorial Sloan Kettering Cancer Center New York NY USA
Department of Urology Motol Hospital University of Praha Prague Czech Republic
Department of Urology Rabin Medical Centre Tel Aviv Israel
Department of Urology Radboud University Nijmegen Medical Centre Nijmegen The Netherlands
Department of Urology Santa Chiara Hospital Trento Italy
Department of Urology Sismanoglio Hospital University of Athens Athens Greece
Department of Urology Weill Medical College of Cornell University New York NY USA
Dipartimento di Urologia Università Vita Salute Ospedale S Raffaele Milan Italy
Facharzt fur Urologie Abteilung fur Urologie Chirurgische Universitats klinik Freiburg Germany
Genetic and Molecular Epidemiology Group Spanish National Cancer Research Centre Madrid Spain
Zobrazit více v PubMed
Svatek RS, Hollenbeck BK, Holmäng S, et al. The economics of bladder cancer: costs and considerations of caring for this disease. Eur Urol. 2014;66(2):253–262. doi:10.1016/j.eururo.2014.01.006. PubMed DOI
Burger M, Catto JWF, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63(2):234–241. doi:10.1016/j.eururo.2012.07.033. PubMed DOI
Babjuk M, Böhle A, Burger M, et al. EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol. 2017;71(3):447–461. doi:10.1016/j.eururo.2016.05.041. PubMed DOI
Sylvester RJ, Van Der Meijden APM, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466–475. doi:10.1016/j.eururo.2005.12.031. PubMed DOI
Fernandez-Gomez J, Madero R, Solsona E, et al. Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in Patients Treated With Bacillus Calmette-Guerin: The CUETO Scoring Model. J Urol 2009;182(5):2195–203 doi:10.1016/j.juro.2009.07.016. PubMed DOI
Xylinas E, Kent M, Kluth L, et al. Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder. Br J Cancer 2013;109(6):1460–6.doi:10.1038/bjc.2013.372. PubMed DOI PMC
Ramirez-Backhaus M, Dominguez-Escrig J, Collado A, Rubio-Briones J, Solsona E. Restaging transurethral resection of bladder tumor for high-risk stage Ta and T1 bladder cancer. Curr Urol Rep. 2012;13(2):109–114. doi:10.1007/s11934-012-0234-4. PubMed DOI
Bishr M, Lattouf JB, Latour M, Saad F. Tumour stage on re-staging transurethral resection predicts recurrence and progression-free survival of patients with high-risk non-muscle invasive bladder cancer. J Can Urol Assoc. 2014;8(5–6):6–10. doi:10.5489/cuaj.1514. PubMed DOI PMC
Herr HW, Donat SM. A re-staging transurethral resection predicts early progression of superficial bladder cancer. BJU Int. 2006;97(6):1194–1198. doi:10.1111/j.1464-410X.2006.06145.x. PubMed DOI
Herr HW, Donat SM, Dalbagni G. Can Restaging Transurethral Resection of T1 Bladder Cancer Select Patients for Immediate Cystectomy? J Urol 2007;177(1):75–9; doi:10.1016/j.juro.2007.08.070. PubMed DOI
Hautmann RE, Volkmer BG, Gust K. QuantiWcation of the survival beneWt of early versus deferred cystectomy in high-risk non-muscle invasive bladder cancer (T1 G3). World J Urol. 2009;27:347–351. doi:10.1007/s00345-009-0402-4. PubMed DOI
Roghmann F, Trinh Q-D, Braun K, et al. Standardized assessment of complications in a contemporary series of European patients undergoing radical cystectomy. Int J Urol. 2014;21(2):143–149. doi:10.1111/iju.12232. PubMed DOI
Nayak JG, Gore JL, Holt SK, Wright JL, Mossanen M, Dash A. Patient-centered risk stratification of disposition outcomes following radical cystectomy. Urol Oncol Semin Orig Investig. 2016;34(5):235.e17–235.e23. doi:10.1016/j.urolonc.2015.11.012. PubMed DOI
Gontero P, Sylvester R, Pisano F, et al. The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Guérin. BJU Int 2016;118(1):44–52 PubMed PMC
Dalbagni G, Vora K, Kaag M, et al. Platinum Priority – Bladder Cancer Clinical Outcome in a Contemporary Series of Restaged Patients with Clinical T1 Bladder Cancer. Eur Urol 2009;56(6):903–10. doi:10.1016/j.eururo.2009.07.005. PubMed DOI PMC
Herr HW. Role of re-resection in non-muscle-invasive bladder cancer. ScientificWorldJournal. 2011;11:283–288. doi:10.1100/tsw.2011.29. PubMed DOI PMC
Gordon P, Thomas PC, Noon AP et al. Long-term outcomes from re-resection for high risk non muscle invasive bladder cancer: a potential to rationalize use. Eur Urol Focus 2017, pii: S2405–4569(17)30241–9. PubMed
Gontero P, Sylvester R, Pisano F, et al. Platinum Priority – Urothelial Cancer Prognostic Factors and Risk Groups in T1G3 Non–Muscle-invasive Bladder Cancer Patients Initially Treated with Bacillus Calmette-Gué rin: Results of a Retrospective Multicenter Study of 2451 Patients. Eur Urol. 2015;7(7):4–8. doi:10.1016/j.eururo.2014.06.040. PubMed DOI
Denzinger S, Fritsche H-M, Otto W, Blana A, Wieland W- F, Burger M. Early Versus Deferred Cystectomy for Initial High-Risk pT1G3 Urothelial Carcinoma of the Bladder: Do Risk Factors Define Feasibility of Bladder-Sparing Approach? Eur Urol. 2008;53(1):146–152. doi:10.1016/j.eururo.2007.06.030. PubMed DOI
Hautmann RE, Volkmer BG, Gust K. Quantification of the survival benefit of early versus deferred cystectomy in high-risk non-muscle invasive bladder cancer (T1 G3). World J Urol. 2009;27(3):347–351. doi:10.1007/s00345-009-0402-4. PubMed DOI
Novotny V, Zastrow S, Koch R, Wirth MP. Radical cystectomy in patients over 70 years of age: impact of comorbidity on perioperative morbidity and mortality. WJUrol 2012;30(6):769–76.doi:10.1007/s00345-011-0782-0. PubMed DOI
Cumberbatch MGK, Foerster Catto JWF. Repeat Transurethral Resection in Non–muscle-invasive Bladder Cancer: A Systematic Review. Eur Urol 2018, article in press. PubMed